GLPG Fundamental Analysis - GALAPAGOS NV-SPON ADR

Fundamental Rating

Taking everything into account, GLPG scores 2 out of 10 in our fundamental rating. GLPG was compared to 534 industry peers in the Biotechnology industry. While GLPG seems to be doing ok healthwise, there are quite some concerns on its profitability. GLPG does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

GLPG had negative earnings in the past year.

In the past year GLPG has reported a negative cash flow from operations.

The reported net income has been mixed in the past 5 years: GLPG reported negative net income in multiple years.

In the past 5 years GLPG always reported negative operating cash flow.

1.2 Ratios

GLPG has a Return On Assets of -7.45%. This is amongst the best in the industry. GLPG outperforms 86.14% of its industry peers.

Looking at the Return On Equity, with a value of -10.75%, GLPG belongs to the top of the industry, outperforming 87.83% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-7.45%
ROE	-10.75%
ROIC	N/A

ROA(3y)0.68%

ROA(5y)-1.06%

ROE(3y)0.5%

ROE(5y)-2.77%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

GLPG's Profit Margin has improved in the last couple of years.

GLPG has a Gross Margin of 87.59%. This is amongst the best in the industry. GLPG outperforms 89.51% of its industry peers.

GLPG's Gross Margin has declined in the last couple of years.

The Profit Margin and Operating Margin are not available for GLPG so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	87.59%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5Y9.7%

GM growth 3Y-4.31%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

GLPG does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for GLPG remains at a similar level compared to 1 year ago.

GLPG has more shares outstanding than it did 5 years ago.

Compared to 1 year ago, GLPG has a worse debt to assets ratio.

2.2 Solvency

GLPG has an Altman-Z score of 1.46. This is a bad value and indicates that GLPG is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of 1.46, GLPG is in the better half of the industry, outperforming 62.92% of the companies in the same industry.

GLPG has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.

GLPG's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. GLPG outperforms 47.38% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	1.46

ROIC/WACCN/A

WACC7.89%

2.3 Liquidity

GLPG has a Current Ratio of 8.08. This indicates that GLPG is financially healthy and has no problem in meeting its short term obligations.

Looking at the Current ratio, with a value of 8.08, GLPG is in the better half of the industry, outperforming 73.60% of the companies in the same industry.

GLPG has a Quick Ratio of 7.99. This indicates that GLPG is financially healthy and has no problem in meeting its short term obligations.

GLPG has a better Quick ratio (7.99) than 73.60% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	8.08
Quick Ratio	7.99

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

GLPG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -200.70%.

Measured over the past years, GLPG shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -12.47% on average per year.

GLPG shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -52.50%.

GLPG shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -20.82% yearly.

EPS 1Y (TTM)-200.7%

EPS 3YN/A

EPS 5Y-12.47%

EPS Q2Q%-1242.86%

Revenue 1Y (TTM)-52.5%

Revenue growth 3Y-20.01%

Revenue growth 5Y-20.82%

Sales Q2Q%-16.16%

3.2 Future

GLPG is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -40.74% yearly.

GLPG is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.05% yearly.

EPS Next Y-346.2%

EPS Next 2Y-84.1%

EPS Next 3Y-65.78%

EPS Next 5Y-40.74%

Revenue Next Year-5.39%

Revenue Next 2Y-2.52%

Revenue Next 3Y-4.07%

Revenue Next 5Y-0.05%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GLPG. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GLPG. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

GLPG's earnings are expected to decrease with -65.78% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-84.1%

EPS Next 3Y-65.78%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for GLPG!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

GALAPAGOS NV-SPON ADR

NASDAQ:GLPG (10/23/2025, 4:10:10 PM)

After market: 32.03 0 (0%)

32.03

+0.16 (+0.5%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)07-23 2025-07-23/amc

Earnings (Next)11-05 2025-11-05

Inst Owners25.23%

Inst Owner Change0.15%

Ins Owners0%

Ins Owner ChangeN/A

Market Cap2.11B

Revenue(TTM)275.61M

Net Income(TTM)-284274000

Analysts48.24

Price Target35.19 (9.87%)

Short Float %3.35%

Short Ratio5.88

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-1378.49%

Min EPS beat(2)-1682.53%

Max EPS beat(2)-1074.45%

EPS beat(4)1

Avg EPS beat(4)-663.96%

Min EPS beat(4)-1682.53%

Max EPS beat(4)154.1%

EPS beat(8)5

Avg EPS beat(8)-142.38%

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)1

Avg Revenue beat(2)-2.96%

Min Revenue beat(2)-10.27%

Max Revenue beat(2)4.35%

Revenue beat(4)1

Avg Revenue beat(4)-8.31%

Min Revenue beat(4)-15.5%

Max Revenue beat(4)4.35%

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0.04%

PT rev (3m)1.22%

EPS NQ rev (1m)0%

EPS NQ rev (3m)86.57%

EPS NY rev (1m)0%

EPS NY rev (3m)-151.06%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)-0.89%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0.99%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	6.61
P/FCF	N/A
P/OCF	N/A
P/B	0.69
P/tB	0.75
EV/EBITDA	N/A

EPS(TTM)-5.02

EYN/A

EPS(NY)-1.81

Fwd EYN/A

FCF(TTM)-5.24

FCFYN/A

OCF(TTM)-4.9

OCFYN/A

SpS4.85

BVpS46.49

TBVpS42.68

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-7.45%
ROE	-10.75%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	87.59%
FCFM	N/A

ROA(3y)0.68%

ROA(5y)-1.06%

ROE(3y)0.5%

ROE(5y)-2.77%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5Y9.7%

GM growth 3Y-4.31%

GM growth 5YN/A

F-Score1

Asset Turnover0.07

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	30.4%
Cap/Sales	7.05%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	8.08
Quick Ratio	7.99
Altman-Z	1.46

F-Score1

WACC7.89%

ROIC/WACCN/A

Cap/Depr(3y)93.66%

Cap/Depr(5y)187.37%

Cap/Sales(3y)17.05%

Cap/Sales(5y)15.82%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-200.7%

EPS 3YN/A

EPS 5Y-12.47%

EPS Q2Q%-1242.86%

EPS Next Y-346.2%

EPS Next 2Y-84.1%

EPS Next 3Y-65.78%

EPS Next 5Y-40.74%

Revenue 1Y (TTM)-52.5%

Revenue growth 3Y-20.01%

Revenue growth 5Y-20.82%

Sales Q2Q%-16.16%

Revenue Next Year-5.39%

Revenue Next 2Y-2.52%

Revenue Next 3Y-4.07%

Revenue Next 5Y-0.05%

EBIT growth 1Y-98.65%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-29.52%

EBIT Next 3Y-12.01%

EBIT Next 5Y14.78%

FCF growth 1Y45.3%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y46.13%

OCF growth 3YN/A

OCF growth 5YN/A

GALAPAGOS NV-SPON ADR (GLPG) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens